The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy
Open accessAbstract
Melittin (MEL), a major peptide component of bee venom, is an attractive candidate for cancer therapy. This agent has shown a variety of anti-cancer effects in preclinical cell culture and animal model systems. Despite a convincing efficacy data against variety of cancers, its applicability to humans has met with challenges due to several issues including its non-specific cytotoxicity, degradation and hemolytic activity. Several optimization approaches including utilization of nanoparticle based delivery of MEL have been utilized to circumvent the issues. Here, we summarize the current understanding of the anticancer effects of bee venom and MEL on different kinds of cancers. Further, we also present the available information for the possible mechanism of action of bee venom and/or MEL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Wang, C., Chen, T., Zhang, N., Yang, M., Li, B., Lü, X., Cao, X., & Ling, C. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m807191200 · Cited by 189
RetractedJemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Apoptosis in cancer: from pathogenesis to treatment
Wong, R. S. (2011) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-30-87 · Cited by 2,836
Current Challenges in Cancer Treatment
Zugazagoitia, J., Guedes, C., Ponce, S., Ferrer, I., Molina-Pinelo, S., & Paz-Ares, L. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.03.026 · Cited by 926
Melittin: a Membrane-active Peptide with Diverse Functions
Raghuraman, H., & Chattopadhyay, A. (2007) · Bioscience Reports · doi:10.1007/s10540-006-9030-z · Cited by 651
SON, D., LEE, J., LEE, Y., SONG, H., LEE, C., & HONG, J. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.04.004 · Cited by 633
Cationic amphiphilic peptides with cancer-selective toxicity
Schweizer, F. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.08.043 · Cited by 517
Dietary phytochemicals and cancer chemoprevention: a review of the clinical evidence
Kotecha, R., Takami, A., & Espinoza, J. L. (2016) · Oncotarget · doi:10.18632/oncotarget.9593 · Cited by 396
Oršolić, N. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9339-3 · Cited by 386
Soman, N. R., Baldwin, S. L., Hu, G., Marsh, J. N., Lanza, G. M., Heuser, J. E., Arbeit, J. M., Wickline, S. A., & Schlesinger, P. H. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38842 · Cited by 293
Kinetics and mechanism of hemolysis induced by melittin and by a synthetic melittin analogue
DeGrado, W. F., Musso, G. F., Lieber, M., Kaiser, E. T., & Kézdy, F. J. (1982) · Biophysical Journal · doi:10.1016/s0006-3495(82)84681-x · Cited by 266
Jo, M., Park, M. H., Kollipara, P. S., An, B. J., Song, H. S., Han, S. B., Kim, J. H., Song, M. J., & Hong, J. T. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2011.10.009 · Cited by 243
Melittin prevents liver cancer cell metastasis through inhibition of the Rac1-dependent pathway
Liu, S., Yu, M., He, Y., Xiao, L., Wang, F., Song, C., Sun, S., Ling, C., & Xu, Z. (2008) · Hepatology · doi:10.1002/hep.22240 · Cited by 206
Why do we study animal toxins?
Zhang, Y. (2015) · PubMed · doi:10.13918/j.issn.2095-8137.2015.4.183 · Cited by 198
Park, M. H., Choi, M. S., Kwak, D. H., Oh, K., Yoon, D. Y., Han, S. B., Song, H. S., Song, M. J., & Hong, J. T. (2011) · The Prostate · doi:10.1002/pros.21296 · Cited by 175
Jang, M.-H., Shin, M.-C., Lim, S., Han, S., Park, H., Shin, I., Lee, J., Kim, K., Kim, E., & Kim, C. (2003) · Journal of Pharmacological Sciences · doi:10.1254/jphs.91.95 · Cited by 161
Perspective of Use of Antiviral Peptides against Influenza Virus
Skalíčková, S., Heger, Z., Krejčová, L., Pekařík, V., Bastl, K., Janda, J., Kostolanský, F., Varečková, E., Zítka, O., Adam, V., et al. (2015) · Viruses · doi:10.3390/v7102883 · Cited by 160
Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin
LeBeau, A. M., Brennen, W. N., Aggarwal, S., & Denmeade, S. R. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1170 · Cited by 159
Heinen, T. E., & da Veiga, A. B. G. (2011) · Toxicon · doi:10.1016/j.toxicon.2011.01.002 · Cited by 149
Moon, D., Park, S.-Y., Heo, M., Kim, K.-C., Park, C., Ko, W. S., Choi, Y. H., & Kim, G. (2006) · International Immunopharmacology · doi:10.1016/j.intimp.2006.07.027 · Cited by 148
Review of the anticancer activities of bee products
Premratanachai, P., & Chanchao, C. (2014) · Asian Pacific Journal of Tropical Biomedicine · doi:10.12980/apjtb.4.2014c1262 · Cited by 143
Soman, N. R., Lanza, G. M., Heuser, J., Schlesinger, P. H., & Wickline, S. A. (2008) · Nano Letters · doi:10.1021/nl073290r · Cited by 140
Huang, C., Jin, H., Qian, Y., Qi, S., Luo, H., Luo, Q., & Zhang, Z. (2013) · ACS Nano · doi:10.1021/nn400683s · Cited by 131
Tumour suppressor genes in chemotherapeutic drug response
Lai, D., Grieve, S., & Yang, X. (2012) · Bioscience Reports · doi:10.1042/bsr20110125 · Cited by 125
Tu, W., Wu, C., Hsieh, H.-L., Chen, C.-Y., & Hsu, S. (2008) · Toxicon · doi:10.1016/j.toxicon.2008.06.007 · Cited by 105
Cytolytic peptide nanoparticles (‘NanoBees’) for cancer therapy
Pan, H., Soman, N. R., Schlesinger, P. H., Lanza, G. M., & Wickline, S. A. (2011) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.126 · Cited by 104
Do, N., Weindl, G., Grohmann, L., Salwiczek, M., Koksch, B., Körting, H. C., & Schäfer‐Korting, M. (2014) · Experimental Dermatology · doi:10.1111/exd.12384 · Cited by 101
Moon, D., Park, S.-Y., Choi, Y. H., Kim, N. D., Lee, C., & Kim, G. (2007) · Toxicon · doi:10.1016/j.toxicon.2007.08.015 · Cited by 92
Melittin derived peptides for nanoparticle based siRNA transfection
Hou, K. K., Pan, H., Lanza, G. M., & Wickline, S. A. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.01.037 · Cited by 91
Melittin peptide kills Trypanosoma cruzi parasites by inducing different cell death pathways
Adade, C. M., Oliveira, I. R., Pais, J. A. R., & Souto-Padrón, T. C. B. S. (2013) · Toxicon · doi:10.1016/j.toxicon.2013.03.011 · Cited by 88
Russell, P. J., Hewish, D. R., Carter, T. E., Sterling-Levis, K., Ow, K. T., Hattarki, M. K., Doughty, L., Guthrie, R. E., Shapira, D. R., Molloy, P. L., et al. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0457-9 · Cited by 87
Holle, L., Song, W., Holle, E., Wei, Y., Wagner, T. E., & Yu, X. (2003) · International Journal of Oncology · doi:10.3892/ijo.22.1.93 · Cited by 81
Model Membrane and Cell Studies of Antimicrobial Activity of Melittin Analogues
Jamasbi, E., Mularski, A., & Separovic, F. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150703115919 · Cited by 81
Shin, J.-M., Jeong, Y., Cho, H.-J., Park, K., Chung, I., Lee, I., Kwak, J., Chang, H., Kim, C., Moon, S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069380 · Cited by 78
15 million new cancer cases per year by 2020, says WHO
Frankish, H. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13038-3 · Cited by 75
Choi, K. U., Hwang, C. J., Sun, G., Park, M., Kim, J., Park, J. Y., Ahn, Y., Kim, J., Song, M. J., Song, H. J., et al. (2014) · Toxins · doi:10.3390/toxins6082210 · Cited by 75
Impact of nanotechnology on the delivery of natural products for cancer prevention and therapy
Siddiqui, I. A., & Sanna, V. (2016) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201600035 · Cited by 73
Self-citationZheng, J., Lee, H. L., Ham, Y. W., Song, H. S., Song, M. J., & Hong, J. T. (2015) · Oncotarget · doi:10.18632/oncotarget.6295 · Cited by 72
Al-Sadoon, M. K., Rabah, D. M., & Badr, G. (2013) · Cellular Immunology · doi:10.1016/j.cellimm.2013.07.016 · Cited by 69
Barrajón‐Catalán, E., Menéndez-Gutierrez, M. P., Falcó, A., Carrato, A., Saceda, M., & Micol, V. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.09.010 · Cited by 67
Huh, J., Kang, J. W., Nam, D., Baek, Y.-H., Choi, D., Park, D., & Lee, J.-D. (2012) · Journal of Natural Products · doi:10.1021/np300446c · Cited by 63
Dual secured nano-melittin for the safe and effective eradication of cancer cells
Cheng, B., Thapa, B., Remant, K. C. B., & Xu, P. (2014) · Journal of Materials Chemistry B · doi:10.1039/c4tb01401d · Cited by 61
Díaz-García, A., Morier-Díaz, L., Frión-Herrera, Y., Rodríguez-Sánchez, H., Lorenzo, Y. C., Llanes, D. M., Garlobo, Y. R., & Castro, J. A. F. (2013) · PubMed Central · Cited by 53
Arora, A. S., de Groen, P. C., Croall, D. E., Emori, Y., & Gores, G. J. (1996) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199606)167:3<434::aid-jcp7>3.0.co;2-q · Cited by 53
Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy
Liu, M., Wang, H., Liu, L., Wang, B., & Sun, G. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0910-0 · Cited by 51
Zhang, H., Zhao, B., Huang, C., Meng, X., Bian, E., & Li, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095520 · Cited by 46
Wu, X., Zhao, B., Cheng, Y., Yang, Y., Huang, C., Meng, X., Wu, B., Zhang, L., Lv, X., & Li, J. (2015) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2015.07.010 · Cited by 43
Chemoprevention: Making it a success story for controlling human cancer
Mukhtar, H. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.05.016 · Cited by 40
Self-citationDelivery of a Protease-Activated Cytolytic Peptide Prodrug by Perfluorocarbon Nanoparticles
Jallouk, A. P., Palekar, R. U., Marsh, J. N., Pan, H., Pham, C. T. N., Schlesinger, P. H., & Wickline, S. A. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00246 · Cited by 40
Alizadehnohi, M., Nabiuni, M., Nazari, Z., Safaeinejad, Z., & Irian, S. (2012) · PubMed · Cited by 39
Cathepsin S silencing induces apoptosis of human hepatocellular carcinoma cells.
Wang, X., Li, X., Yu, G., et al. (2015) · PubMed · Cited by 37
Diet phytochemicals and cutaneous carcinoma chemoprevention: A review
Wang, S., Shen, P., Zhou, J., & Lu, Y. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.02.021 · Cited by 34
Defined Nanoscale Chemistry Influences Delivery of Peptido-Toxins for Cancer Therapy
Misra, S. K., Ye, M., Kim, S., & Pan, D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125908 · Cited by 32
Alonezi, S., Tusiimire, J., Wallace, J., Dufton, M. J., Parkinson, J. A., Young, L., Clements, C. J., Park, J. M., Jeon, J., Ferro, V. A., et al. (2016) · Metabolites · doi:10.3390/metabo6040035 · Cited by 31
Shin, M. C., Min, K. A., Cheong, H., Moon, C., Huang, Y., He, H., & Yang, V. C.-M. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1959-4 · Cited by 28
Human Cancer Chemoprevention: Hurdles and Challenges
Adhami, V. M., & Mukhtar, H. (2012) · Topics in current chemistry · doi:10.1007/128_2012_342 · Cited by 26
Self-citationCancer chemoprevention is not a failure
Adhami, V. M., Bailey, H. H., & Mukhtar, H. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu141 · Cited by 24
Self-citationWang, D., Hu, L., Su, M., Wang, J., & Xu, T. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3078 · Cited by 18
Expression and anticancer activity analysis of recombinant human uPA1–43-melittin
Su, M., Chang, W., Cui, M., Yang, L., Wu, S., & Xu, T. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2750 · Cited by 14
Kollipara, P. S., Kim, J., Won, D., Lee, S. M., Sung, H. C., Chang, H. S., Lee, K. T., Lee, K. S., Park, M. H., Song, M. J., et al. (2013) · Archives of Pharmacal Research · doi:10.1007/s12272-013-0319-8 · Cited by 14
Cited by
Insect Antimicrobial Peptides, a Mini Review
Wu, Q., Patočka, J., & Kuča, K. (2018) · Toxins · doi:10.3390/toxins10110461 · Cited by 481
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Bee Venom: Overview of Main Compounds and Bioactivities for Therapeutic Interests
Wehbe, R., Frangieh, J., Rima, M., El Obeid, D., Sabatier, J.-M., & Fajloun, Z. (2019) · Molecules · doi:10.3390/molecules24162997 · Cited by 372
Insect antimicrobial peptides: potential weapons to counteract the antibiotic resistance
Manniello, M. D., Moretta, A., Salvia, R., Scieuzo, C., Lucchetti, D., Vogel, H., Sgambato, A., & Falabella, P. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03784-z · Cited by 259
Anti-fungal properties and mechanisms of melittin
Memariani, H., & Memariani, M. (2020) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-020-10701-0 · Cited by 58
Metadata
- Authors
- Rady, I., Siddiqui, I. A., Rady, M., & Mukhtar, H.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2017-08
- Volume
- 402
- Pages
- 16-31
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W2614874910
- Cited by
- 387
- References
- 63
- FWCI
- 16.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.